An update on ketamine and its two enantiomers as rapid-acting antidepressants
The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Introduction : Depression is one of the most disabling diseases worldwide. Approximately one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months. There is a clear unmet need for rapid-acting and more efficacious treatments. ( R,S )-ketamine, an old anesthetic drug, appears now to be going through a renaissance. Areas covered : This paper reviews recent literature describing the antidepressant effects of ketamine and its enantiomer ( S )-ketamine in patients with major depressive disorder (MDD) and bipolar disorder (BD). Furthermore, the authors discuss the therapeutic potential of ( R )-ketamine, another enantiomer of ( R,S )-ketamine, and ( S )-norketamine. Expert commentary : A number of clinical studies have demonstrated that ( R,S )-ketamine has rapid-acting and sustained antidepressant activity in treatment-resistant patients with MDD, BD, and other psychiatric disorders. Off-label use of ketamine for mood disorders is proving popular in the United States. Meanwhile, preclinical data suggests that ( R )-ketamine can exert longer-lasting antidepressant effects than ( S )-ketamine in animal models of depression, and ( R )-ketamine may have less detrimental side effects than ( R,S )-ketamine and ( S )-ketamine. Additionally, ( S )-norketamine exhibits rapid and sustained antidepressant effects, with a potency similar to that of ( S )-ketamine. Unlike ( S )-ketamine,…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intravenous administration provides the most predictable dosing with 100% bioavailability, and availability via other routes of administration including intranasal (45%), sublingual (30%), oral (20%), intramuscular (93%) and rectal (30%) is discussed in the literature.31,34,35,46,54”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [54]
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258
RetractedAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“of new spine synapses through activated the mTOR signaling pathway in the rat prefrontal cortex [54,55].”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
The Epidemiology of Post-Traumatic Stress Disorder after Disasters
Galea, S., Nandi, A., & Vlahov, D. (2005) · Epidemiologic Reviews · doi:10.1093/epirev/mxi003 · Cited by 1,287 · cited 1×
“PTSD has a lifetime prevalence of approximately 10%, with women having a twofold greater risk than men [32].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“[10] used an active placebo, midazolam, because of its intravenously availability and ketamine-like pharmacokinetics.”
MethodDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Research works printed but not linked: 2
- Mastrodonato A, Biol Psychiatry
- Zhang K, 2018, Int J Neuropsychopharmacol
Cited by
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Therefore, predictable biomarkers that distinguish responders or non-responders to ketamine are necessary.(10) The Val/Val carrier (rs6265) in the brain-derived neurotrophic factor (BDNF) gene in MDD patients shows a higher ketamine response than the Met carriers,(67) suggesting that the Val66Met polymorphism in the B…”
BackgroundSelf-citationPharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“However, this same dose of (R)-ketamine did not produce CPP in a different study [68] and was 4 times the dose needed (typically 10 mg/kg) to elicit antidepressant-like effects in mice and rats [19, 70, 71].”
BackgroundIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Self-citation
Metadata
- Authors
- Zhang, K., & Hashimoto, K.
- Affiliations
- Chiba University (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2018-12-04
- Volume
- 19
- Issue
- 1
- Pages
- 83-92
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2902748937
- Cited by
- 132
- References
- 97
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 33 · 2023: 8 · 2022: 19 · 2021: 20 · 2020: 25 · 2019: 17 · 2018: 1
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Neurotherapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP18dm0107119)
- Medical and Public Health Technology Research Projects of Wuxi Technology Bureau (CSE31N1723 and CSE31N1613)
- Wuxi Municipal Health and Family Planning Commission research project (MS201704)
- National Nature Science Foundation of China (81801341)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, (R)-ketamine, rapid-acting antidepressants, major depressive disorder, bipolar disorder, treatment-resistant depression, enantiomers, off-label drug use, antidepressant side effects
- MeSH terms
- Animals, Antidepressive Agents, Depressive Disorder, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on ketamine and its two enantiomers as rapid-acting antidepressants. https://app.cochat.ai/papers/10.1080/14737175.2019.1554434
- The paper
- Zhang, K., & Hashimoto, K. (2019). An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1554434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.